Drug price reforms still don't scare Wall Street

Wall Street still mostly believes President Trump's drug pricing blueprint doesn't present any immediate, large-scale disruptions to the industry as the Trump administration remains focused on changing things like rebates instead of lowering net prices.

What they're saying: "Successful efforts at lowering out-of-pocket spend for patients could ultimately help boost volumes and be a positive for the [pharmaceutical] group, but at minimum things seem to be heading in a direction that is at least neutral for the group and likely much better than previously feared." — Vamil Divan, pharma analyst at Credit Suisse, in a note to investors this month